IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 149 filers reported holding IMMUNOVANT INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,183,146 | +296.8% | 82,916 | +60.3% | 0.00% | – |
| Q2 2023 | $802,208 | 0.0% | 51,722 | 0.0% | 0.00% | – |
| Q1 2023 | $802,208 | +3.3% | 51,722 | +18.2% | 0.00% | – |
| Q4 2022 | $776,633 | -99.6% | 43,754 | +17.2% | 0.00% | – |
| Q3 2022 | $208,385,000 | +2.9% | 37,345 | -28.1% | 0.00% | – |
| Q2 2022 | $202,575,000 | -29.2% | 51,942 | 0.0% | 0.00% | – |
| Q1 2022 | $286,200,000 | -35.3% | 51,942 | 0.0% | 0.00% | – |
| Q4 2021 | $442,545,000 | -2.0% | 51,942 | 0.0% | 0.00% | – |
| Q3 2021 | $451,376,000 | -29.1% | 51,942 | -13.7% | 0.00% | – |
| Q2 2021 | $636,282,000 | -8.9% | 60,197 | +38.2% | 0.00% | – |
| Q1 2021 | $698,494,000 | -66.1% | 43,547 | -2.5% | 0.00% | -100.0% |
| Q4 2020 | $2,061,968,000 | +193.0% | 44,641 | +123.2% | 0.00% | – |
| Q3 2020 | $703,800,000 | +224.8% | 20,000 | +124.7% | 0.00% | – |
| Q2 2020 | $216,715,000 | – | 8,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |